Literature DB >> 29983287

Sequence heterogeneity of the PenA carbapenemase in clinical isolates of Burkholderia multivorans.

Scott A Becka1, Elise T Zeiser1, Steven H Marshall1, Julian A Gatta1, Kevin Nguyen2, Indresh Singh2, Chris Greco2, Granger G Sutton2, Derrick E Fouts2, John J LiPuma3, Krisztina M Papp-Wallace4.   

Abstract

Multidrug-resistant gram-negative pathogens are a significant health threat. Burkholderia spp. encompass a complex subset of gram-negative bacteria with a wide range of biological functions that include human, animal, and plant pathogens. The treatment of infections caused by Burkholderia spp. is problematic due to their inherent resistance to multiple antibiotics. The major β-lactam resistance determinant expressed in Burkholderia spp. is a class A β-lactamase of the PenA family. In this study, significant amino acid sequence heterogeneity was discovered in PenA (37 novel variants) within a panel of 48 different strains of Burkholderia multivorans isolated from individuals with cystic fibrosis. Phylogenetic analysis distributed the 37 variants into 5 groups based on their primary amino acid sequences. Amino acid substitutions were present throughout the entire β-lactamase and did not congregate to specific regions of the protein. The PenA variants possessed 5 to 17 single amino acid changes. The N189S and S286I substitutions were most prevalent and found in all variants. Due to the sequence heterogeneity in PenA, a highly conserved peptide (18 amino acids) within PenA was chosen as the antigen for polyclonal antibody production in order to measure expression of PenA within the 48 clinical isolates of B. multivorans. Characterization of the anti-PenA peptide antibody, using immunoblotting approaches, exposed several unique features of this antibody (i.e., detected <500 pg of purified PenA, all 37 PenA variants in B. multivorans, and Pen-like β-lactamases from other species within the Burkholderia cepacia complex). The significant sequence heterogeneity found in PenA may have occurred due to selective pressure (e.g., exposure to antimicrobial therapy) within the host. The contribution of these changes warrants further investigation. Published by Elsevier Inc.

Entities:  

Keywords:  Burkholderia; Sequencing; β-Lactamase

Mesh:

Substances:

Year:  2018        PMID: 29983287      PMCID: PMC6173980          DOI: 10.1016/j.diagmicrobio.2018.06.005

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


1. Introduction

The genus Burkholderia encompasses ~114 to 117 species that include human, animal, and/or plant pathogens as well as species that possess environmental benefits (e.g., endophytic B. phytofirmans can prevent onion rot) (Eberl and Vandamme, 2016). Based on advances in whole genomic sequencing and phylogenetic analysis, researchers proposed reorganizing the plant-beneficial-environmental species into new genera, Paraburkholderia and Caballeronia, while the human pathogens would remain within the Burkholderia genus (Dobritsa et al., 2017; Dobritsa and Samadpour, 2016; Eberl and Vandamme, 2016; Sawana et al., 2014). Discrepancies remain, however, as some species possess dual beneficial and pathogenic potential (Paraburkholderia ginsengisoli and Paraburkholderia tropica) (Deris et al., 2010; Marks et al., 2016). Thus, the taxonomic organization of these species remains controversial. Focusing on the Burkholderia pathogens, 2 major groups exist, the Burkholderia cepacia complex (Bcc) and the Burkholderia pseudomallei complex (Bpc). Bcc species can cause infections (e.g., pneumonia) in immunocompromised persons or in individuals with cystic fibrosis (Abbott and Peleg, 2015; Chiappini et al., 2014; Gautam et al., 2011; Hanulik et al., 2013; Marson et al., 2015). Among the Bcc, Burkholderia multivorans and Burkholderia cenocepacia are the most prevalent species recovered from persons with cystic fibrosis in the United States. Within the Bpc, B. pseudomallei is capable of causing a necrotizing pneumonia known as melioidosis and is considered a potential bioweapon (Perumal Samy et al., 2017). Bcc and Bpc species are typically antibiotic resistant, rendering effective antimicrobial therapy of infections a challenge (Abbott and Peleg, 2015; Chiappini et al., 2014; Lipuma, 2010; Rhodes and Schweizer, 2016). A major antibiotic resistance determinant present in all species of Burkholderia is an inducible class A β-lactamase of the Pen family (e.g., PenA). In 2009, Poirel et al. (2009) characterized several Pen β-lactamases present in Bcc and published the initial nomenclature for the Pen-like β-lactamase family. Since that time, the number of Burkholderia species has increased as has the number of Pen-type enzymes (Table 1). Expression of blapen genes is regulated by a LysR-type transcriptional regulator, PenR through a system analogous to AmpC/AmpR regulatory pathways present in members of the Enterobacteriaceae and in Pseudomonas aeruginosa (Dhar et al., 2018; Trepanier et al., 1997). In addition, each Pen-like β-lactamase possesses a different substrate profile (Papp-Wallace et al., 2013a; Poirel et al., 2009). PenA of B. multivorans possesses a very broad substrate profile that includes carbapenems and is capable of hydrolyzing β-lactamase inhibitors (i.e., clavulanic acid, sulbactam, and tazobactam). Here, we describe the identification of 37 novel PenA variants from B. multivorans. Moreover, using sequence analysis, we generated a polyclonal antibody using on an antigen that comprised an 18-amino-acid peptide from PenA that is able to detect all of the different PenA variants via immunoblotting.
Table 1

The Pen family of Burkholderial class A β-lactamases.

Bacterial species (complex)Pen-like β-lactamaseReference
Burkholderia multivorans (Bcc)PenA(Trepanier et al., 1997)
Burkholderia cenocepacia (Bcc)PenB(Poirel et al., 2009)
Burkholderia stabilis (Bcc)PenC(Poirel et al., 2009)
Burkholderia pyrrocina (Bcc)PenD(Poirel et al., 2009)
Burkholderia vietnamiensis (Bcc)PenE(Poirel et al., 2009)
Burkholderia ambifaria (Bcc)PenF(Poirel et al., 2009)
Burkholderia dolosa (Bcc)PenG(Poirel et al., 2009)
Burkholderia ubonensis (Bcc)PenH(Poirel et al., 2009)
Burkholderia pseudomallei (Bpc)PenI(Poirel et al., 2009)
Burkholderia oklahomensis (Bpc)PenJ(Poirel et al., 2009)
Burkholderia mallei (Bpc)PenK(Poirel et al., 2009)
Burkholderia thailandensis (Bpc)PenL(Poirel et al., 2009)
Burkholderia humptydooensis (Bpc)PenMThis study
Burkholderia gladioliPenNThis study

2. Materials and methods

2.1. Strains

The Burkholderia spp. clinical isolates were from the B. cepacia Research Laboratory and Repository strain collection as previously described (Papp-Wallace et al., 2017b). The construction of Escherichia coli DH10B pBC SK(+)blapenA and E. coli DH10B pBC SK(+)blapenI was as described (Papp-Wallace et al., 2013b).

2.2. Whole-genome sequencing of B. multivorans

Genomic DNA was purified from the clinical B. multivorans isolates using the MasterPure™ gram-positive DNA purification kit (Epicentre Inc, Madison, WI) as recommended by the manufacturer. The genomes of 48 B. multivorans isolates were sequenced at JCVI by Illumina NextSeq (2 × 150 bp). Paired-end libraries were constructed using Illumina NexteraXT kits. Sequence reads were generated with a target average read depth of ~100-fold coverage. Sequence reads for each isolate were assembled individually using SPAdes (Bankevich et al., 2012) and annotated using National Center for Biotechnology Information’s (NCBI’s) Prokaryotic Genome Annotation Pipeline (Tatusova et al., 2016). Raw DNA sequence reads were submitted to the NCBI Sequence Read Archive, and annotated genomes were deposited in the GenBank whole-genome sequencing repository, which can be obtained within BioProject PRJNA434393. Clustal Ω from the European Bioinformatics Institute (EMBL-EBI) was used to create a multiple sequence alignment using the primary amino acid sequences of the 37 PenA variants and a phylogenetic tree (Li et al., 2015; McWilliam et al., 2013; Sievers et al., 2011).

2.3. PCR and DNA sequencing of blapen from Burkholderia spp

Overnight cultures of B. cenocepacia AU0583, Burkholderia pyrrocinia AU1114, Burkholderia vietnamiensis AU3578, Burkholderia ambifaria AU5203, Burkholderia stabilis AU9035, Burkholderia dolosa AU9336, Burkholderia gladioli AU1009, and Burkholderia ubonensis AU7314 carrying different blaPen genes were boiled for 10 minutes at 99 °C. Polymerase chain reaction (PCR) was conducted using 1 μL of boiled cells (containing the extracted DNA) with the PCR Master Mix (Promega) and primers generated to detect blapenB, blapenC, blapenD, blapenE, blapenF, blapenG, blapenH, and blapenN (Supplementary Table 1). The PCR products were cleaned using QIAquick PCR Purification Kit (Qiagen) and sent to Molecular Cloning Laboratories for DNA sequencing. The resulting DNA sequence files were analyzed using DNAstar software, and the final nucleotide sequences were submitted to NCBI and assigned the following Genbank accession numbers: MG839177–MG839184. Peptide sequences from the different Pen-like β-lactamases were aligned using Clustal Ω as described above.

2.4. Immunoblotting

All strains were grown in lysogeny broth to log phase at an OD600nm between 0.6 and 0.7. In addition, the Burkholderia spp. were treated with 1 mg/L imipenem for 2 hours to induce expression of blapen. Subsequently, the cells were pelleted and lysed using stringent periplasmic fractionation to prepare crude extracts, as previously described (Papp-Wallace et al., 2012). These crude extracts and purified full-length PenA protein were subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes. The membranes were blocked in 5% nonfat dry milk in 20 mM Tris–Cl with 150 mM NaCl at pH 7.4 (TBS) for 1 hour and probed in 5% nonfat dry milk in TBS with 1 μg/mL of polyclonal anti–PenA-peptide antibody (which was raised in rabbits by New England Peptide (NEP) using a selected PenA 18 amino acid peptide as the antigen). Membranes were washed 5 times for 10 minutes with TBS with 0.05% Tween 20 (TBST), and for protein detection, blots were incubated for 1 hour in 1:5000 dilutions of antirabbit and antimouse secondary horseradish peroxidase–conjugated antibodies in 5% nonfat dry milk in TBS. Blots were washed 5 times for 10 minutes with TBST and developed using the ECL-Plus™ developing kit (GE Healthcare Life Sciences) or the SuperSignal West Femto Chemiluminescent Substrate (Thermoscientific) according to the manufacturers’ instructions. The Fotodyne Luminary/FX was used to capture images.

3. Results and discussion

3.1. The PenA carbapenemase of B. multivorans exhibits considerable sequence heterogeneity

To determine the primary amino acid sequence diversity between PenA’s in B. multivorans, we compared the PenA amino acid sequences from 48 different clinical isolates; 37 novel PenA variants were identified (Table 2). PenA variants possessed 5 to 17 different amino acid substitutions (amino acid numbering is based on the Ambler system; Ambler, 1980) compared with PenA from B. multivorans ATCC 17616, the strain in which PenA was first described (Prince et al., 1988). The locations of these amino acid substitutions were mapped to the PenA crystal structure (Fig. 1A). Several amino acid substitutions (N104S, N132S, L169P, and N170K) were found within the motifs associated with the active site (Fig. 1B). These amino acid substitutions are likely to alter the activity of PenA. Previously, amino acid substitutions at position L169 in PenA were shown to possess enhanced ceftazidime resistance (Papp-Wallace et al., 2017a; Yi et al., 2012). Moreover, substitutions at residues N104, N132, and N170 in other class A β-lactamases were shown to influence either the binding of β-lactams and/or β-lactamase inhibitors as well as the turnover or inhibition (Frase et al., 2011; Ourghanlian et al., 2017; Ramdani-Bouguessa et al., 2011).
Table 2

Amino acid comparison of the PenA variants sequenced in clinical isolates of B. multivorans to B. multivorans ATCC 17616; (L), correspond to amino acid substitutions in the PenA leader peptide; and amino acid numbering is based on the Ambler system (Ambler, 1980).

StrainAmino acid substitutions, insertions, or deletions presentNo. of ΔsPenA allelePenA RefSeq accessionGenBank genome accession
ATCC 17616, AU217470PenA1WP_012216561.1NC_010086, PVGM00000000
AU17545, AU19729S(L5)P, N189S, V247A, T267A, S286I5PenA2WP_105796499.1PVGB00000000, PVGH00000000
AU11233T19A, N189S, V247A, T267A, S286I5PenA3WP_105769622.1PVFL0000000
AU26250, AU15954, AU22892H60Y, N189S, V247A, T267A, S286I, A290G6PenA4WP_105781374.1PVGY00000000, PVFW00000000, PVGO00000000
AU10398S(L5)P, T19A, N170K, N189S, V247A, T267A, S286I7PenA5WP_105822028.1PVFH00000000
AU19518, AU28069S(L5)P, N189S, A205T, G228A, V247A, T267A, S286I7PenA6WP_105803562.1PVGD00000000, PVHB00000000
AU14371, AU10897S(L5)P, N189S, A205T, V247A, T267A, S286I, A290G7PenA7WP_105758546.1PVFT00000000, PVFI00000000
AU14786S(L5)P, T19A, G77A, N189S, V247A, T267A, S286I7PenA8WP_048804470.1PVFU00000000
AU25543T19A, G77A, A86E, N189S, P201A, V247A, T267A, S286I8PenA9WP_105772526.1PVGX00000000
AU19564A30V, N189S, V192M, V247A, T267A, S286I, A287S, A290G8PenA10WP_105846710.1PVGE00000000
AU13919, AU14328T19A, F34L, N189S, A205T, V247A, T267A, S286I, A290G8PenA11WP_105777201.1PVFQ00000000, PVFR00000000
AU23995T19A, S25L, T52A, N189S, V247A, T267A, S286I, A290G8PenA12WP_105809721.1PVGT00000000
AU11772, AU23919S(L5)P, T19A, P67R, G77A, N189S, V247A, T267A, S286I8PenA13WP_105766562.1PVFN00000000, PVGS00000000
AU18096T19A, G77A, A86E, N189S, P201A, V247A, T267A, S286I8PenA14WP_105772526.1PVGC00000000
AU21015S(L5)P, P26R, N189S, D239A, V247A, T267A, S286I, A290G8PenA15WP_107999608.1PZZC00000000
AU30760T19A, H60Y, G77A, N189S, P201A, V247A, T267A, S286I, A290G9PenA16WP_105825204.1PVHJ00000000
AU4507A24P, A30S, N189S, P201H, G228A, V247A, T267A, S286I, A290G9PenA17WP_105951298.1PVHL00000000
AU24277S(L5)P, A15T, T19A, N189S, P201L, V247A, T267A, S286I, A290G9PenA18WP_105835300.1PVGU00000000
AU12481T19A, A30S, H60Y, G77A, N189S, V247A, T267A, S286I, A290P9PenA19WP_105791036.1PVFO00000000
AU30441T19A, S25L, T52A, G77A, N189S, V247A, T267A, S286I, A290G9PenA20WP_088926609.1PVHH00000000
AU20929S(L5)P, A23T, N189S, P201A, I208S, G228A, V247A, T267A, S286I, A290G10PenA21WP_105841035.1PVGJ00000000
AU29198S(L5)P, ΔA29, A30L, N189S, P201A, G228A, V247A, T267A, S286I, A290G10PenA22WP_105842598.1PVHD00000000
AU17534T19A, A30S, Q92R, N189S, Q206R, G228A, V247A, T267A, S286I10PenA23WP_105782476.1PVGA00000000
AU23668T(L2)P, S(L5)P, T19A, A30S, H60Y, G77A, N189S, V247A, T267A, S286I10PenA24WP_105813799.1PVGQ00000000
AU21596T19A, A30S, T52A, H60Y, G77A, N189S, V247A, T267A, D276E, S286I10PenA25WP_105854385.1PVGL00000000
AU14364S(L5)P, T19A, A23T, H60Y, D63G, G77A, L169P, A184E, N189S, V247A, T267A, S286I12PenA26WP_105765688.1PVFS00000000
AU15814S(L5)P, T19A, A23T, H60Y, D63G, G77A, N132S, A184E, N189S, V247A, T267A, S286I12PenA27WP_105765076.1PVFV00000000
AU17135, AU10047T3A, L10V, T19A, A58T, N104S, R141L, N189S, P201A, V247A, A280T, S286I, A290G12PenA28WP_088924033.1PVFZ00000000, PVFE00000000
AU16734T3A, L10V, T19A, R99Q, N104S, R141L, N189S, P201A, T227A, A280T, S286I, A290G12PenA29WP_105792310.1PVFY00000000
AU19659T3A, L10V, P26A, A58T, N104S, R141L, N189S, P201A, K219R, A280T, S286I, A290G12PenA30WP_105807557.1PVGF00000000
AU10086T19A, S25L, T52A, G77A, H112Y, T118A, N189S, V247A, T267A, R283Q, S286I, A290G12PenA31WP_039217008.1PVFF00000000
AU23690, AU11358, AU11204T3A, L10V, T19A, A58T, N104S, R141L, N189S, P201A, T227A, V247A, A280T, S286I, A290G13PenA32WP_105762373.1PVGR00000000, PVFM00000000, PVFK00000000
AU23365T3A, L10V, T19A, N104S, R141L, N189S, P201A, T227A, V247A, L250M, A280T, S286I, A290G13PenA33WP_069220914.1PVGP00000000
AU27706T3A, L10V, T19A, N104S, R141L, N189S, insertion VL 191–192, P201A, T227A, V247A, L250M, A280T, S286I, A290G15PenA34WP_105856053.1PVHA00000000
AU30050T3A, L10V, T19P, V20T, S21D, D22N, V27G, N104S, R141L, N189S, P201A, T227A, V247A, A280T, S286I, A290G16PenA35WP_105795180.1PVHF00000000
AU30438T3A, L10V, T19P, V20T, S21D, D22N, V27G, N104S, R141L, N189S, P201A, T227A, V247A, T267A, S286I, A290G16PenA36WP_105795180.1PVHG00000000
AU22436T3A, L10V, T19P, V20T, S21D, D22N, V27G, A58T, N104S, R141L, N189S, P201A, T227A, L250M, A280T, S286I, A290G17PenA37WP_088929369.1PVGN00000000
AU25057T3A, L10V, G11C, T19P, V20T, S21D, D22N, V27G, N104S, R141L, N189S, P201A, T227A, V247A, A280T, S286I, A290G17PenA38WP_105837729.1PVGW00000000
Fig. 1

A, PenA crystal structure representing residues (yellow sticks) that are variable in the different clinical isolates. A gray circle highlights the location of the active site, catalytic S70 (cyan sticks). Bg, Enlarge view of the PenA active site revealing the active site residues (N104, N132, L169, and N170) that possess amino acid substitutions in the PenA variants. C, Phylogenetic tree constructed using Clustal Ω reveals the presence of 5 clades; PenA1 is highlighted in blue (Li et al., 2015; McWilliam et al., 2013; Sievers et al., 2011)

The 37 variants clustered into ~5 clades based on phylogenetic analysis (Fig. 1C). The N189S and S286I amino acid substitutions were found in all PenA variants. Other prevalent amino acid substitutions included V247A and T267A present in 92% and 73% of the variants, respectively. The largest cluster (2) consisted of the 13 variants with a high occurrence of T19A, H60Y, and G77A substitutions (Fig. 1C and Table 2). The second largest group (3) possessed the most (i.e., 12–17) amino acid substitutions in PenA. The majority of these variants carried the T3A, L10V, N104S, and R141L amino acid substitutions, as well as T227A and A280T, which were not present in the other 4 subgroups. The remaining 3 clades contained 4–6 variants; however, the differentiating factor between them included the occurrence of T19A, T52A, and/or S25L in group 1 and P201X and/or G228A in group 4. Clade 5 mostly possessed the prevalent amino acid substitutions mentioned above with a few others interspersed.

3.2. Identification of a PenA peptide for antibody production

Due to the significant heterogeneity in amino acid sequence, the polyclonal anti-PenA antibody that we had generated previously (Papp-Wallace et al., 2017a) using the full-length purified PenA β-lactamase as the antigen was unable to recognize the PenA variants in the clinical isolates via immunoblotting. Thus, we set out to generate a better anti-PenA antibody. Based on the 37 different PenA amino acid sequences, we identified conserved regions within the protein (Fig. 2). Four regions of PenA were found to not possess any amino acid substitutions. With additional guidance provided by NEP, a single PenA-peptide (CARSIGDDTFRLDRWETE; the first amino acid of this peptide, tyrosine [Y] was replaced by cysteine [C]) was chosen for polyclonal antibody production in rabbits (Fig. 2).
Fig. 2

Based on the amino acid sequence variability observed with PenA in the 50 clinical isolates (Table 2), 4 regions (highlighted in green, yellow, cyan, and magenta) were identified within the PenA amino acid sequence that did not possess any substitutions (top); regions are mapped onto the PenA proteins structure (below). NEP conducted further analysis and found that the yellow region (bold and underlined) would make the most favorable antigen.

3.3. The polyclonal anti–PenA-peptide antibody possesses a low limit of detection

To determine the limits of detection for the anti–PenA-peptide antibody, decreasing concentrations (10 fg–5 ng) of purified PenA protein were used for an immunoblot. The antibody could distinguish small amounts of protein, and a band for 500 pg of purified PenA was easily detected; moreover, a very weak band was observed at 100 pg (Fig. 3A). Our previous polyclonal anti-PenA antibody could only recognize 250 ng of purified PenA protein (data not shown). Thus, the anti–PenA-peptide antibody discriminates 200–500× better than the former anti-PenA antibody. The detection limit of the antibody was further assessed using B. multivorans ATCC 17616 after induction of blaPenA using imipenem. The anti–PenA-peptide antibody could detect PenA protein using ~106 CFUs (Fig. 3B).
Fig. 3

Determining the sensitivity of the anti–PenA-peptide antibody. A, Immunoblot using decreasing concentrations of purified PenA β-lactamase. B, Immunoblot using decreasing CFUs of B. multivorans ATTC 17616 after induction with 1 μg/mL of imipenem.

3.4. The polyclonal anti–PenA-peptide antibody detects PenA in 50 different B. multivorans clinical isolates

To test the ability of the anti–PenA-peptide antibody to detect different variants of PenA, 50 B. multivorans clinical isolates were grown to log phase, induced with imipenem, and prepared for immunoblotting. The anti–PenA-peptide antibody was able to detect all 37 PenA variants within the 50 isolates (Fig. 4). A nonspecific higher-molecular-weight band was observed in some of the isolates (e.g., AU29198, AU14786, and AU22436); studies are underway to identify this protein. We speculate that the higher-molecular-weight band represents unprocessed PenA protein prior to cleavage of the signal peptide; PenA’s signal peptide is 27 amino acids and 2.7 kDa.
Fig. 4

Immunoblot on crude extracts of 50 different clinical isolates of B. multivorans after induction with 1 μg/mL of imipenem. Strains AU25626 and AU21251 were not sequenced, but are presented in the immunoblot.

3.5. The polyclonal anti–PenA-peptide antibody detects other Pen-like β-lactamases within Bcc

The cross-reactivity of the PenA-peptide antibody was assessed against other Pen-like β-lactamases (PenB, PenC, PenD, PenE, PenF, PenG, PenH, and PenN) produced by Burkholderia species. Interestingly, among the clinical isolates tested using ~108 CFUs, the antibody detected PenB, PenD, PenE, PenF, PenC, PenG, and PenH, which are produced by strains within the Bcc (Fig. 5A). The PenE and PenG β-lactamases of B. vietnamiensis and B. dolosa, respectively, demonstrated the most intense bands. The PenN β-lactamase of B. gladioli, which is not a member of the Bcc, was not within the limit of detection. Comparison of the analogous peptide sequences from the different Pens revealed that the PenN peptide possessed the most sequence diversity with 4-amino-acid substitutions compared with the peptide used for antibody production (Fig. 5B).
Fig. 5

Assessing the cross-reactivity of anti–PenA-peptide antibody against Burkholderia spp. A, Immunoblot on B. multivorans ATTC 17616 blaPenA, B. cenocepacia AU0583 blaPenB, B. pyrrocinia AU1114 blaPenD, B. vietnamiensis AU3578 blaPenE, B. ambifaria AU5203 blaPenF, B. stabilis AU9035 blaPenC, B. dolosa AU9336 blaPenG, B. gladioli AU1009 blaPenN and B. ubonensis AU7314 blaPenH grown to log phase, induced with 1 μg/mL of imipenem, and prepared as crude extracts. B, Clustal Ω sequence alignment of the peptides from the different Pen-like β-lactamases compared with the PenA peptide used for antibody production.

4. Conclusions

Here, we document the significant sequence heterogeneity in the PenA carbapenemase based on the analysis of 48 different clinical strains of B. multivorans. Thirty-seven novel PenA variants were identified with 5–17 different single amino acid substitutions. Most of the amino acid changes are not to active site residues; thus, we hypothesize that they may increase the stability of the β-lactamase. The impact is currently under investigation.
  32 in total

Review 1.  Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies.

Authors:  Iain J Abbott; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

2.  Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator.

Authors:  S Trépanier; A Prince; A Huletsky
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 3.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

4.  Importance of position 170 in the inhibition of GES-type β-lactamases by clavulanic acid.

Authors:  Hilary Frase; Marta Toth; Matthew M Champion; Nuno T Antunes; Sergei B Vakulenko
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

5.  Understanding the molecular determinants of substrate and inhibitor specificities in the Carbapenemase KPC-2: exploring the roles of Arg220 and Glu276.

Authors:  Krisztina M Papp-Wallace; Magdalena A Taracila; Kerri M Smith; Yan Xu; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

Review 6.  Antibiotic resistance in Burkholderia species.

Authors:  Katherine A Rhodes; Herbert P Schweizer
Journal:  Drug Resist Updat       Date:  2016-07-30       Impact factor: 18.500

7.  Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega.

Authors:  Fabian Sievers; Andreas Wilm; David Dineen; Toby J Gibson; Kevin Karplus; Weizhong Li; Rodrigo Lopez; Hamish McWilliam; Michael Remmert; Johannes Söding; Julie D Thompson; Desmond G Higgins
Journal:  Mol Syst Biol       Date:  2011-10-11       Impact factor: 11.429

8.  The EMBL-EBI bioinformatics web and programmatic tools framework.

Authors:  Weizhong Li; Andrew Cowley; Mahmut Uludag; Tamer Gur; Hamish McWilliam; Silvano Squizzato; Young Mi Park; Nicola Buso; Rodrigo Lopez
Journal:  Nucleic Acids Res       Date:  2015-04-06       Impact factor: 16.971

9.  Analysis Tool Web Services from the EMBL-EBI.

Authors:  Hamish McWilliam; Weizhong Li; Mahmut Uludag; Silvano Squizzato; Young Mi Park; Nicola Buso; Andrew Peter Cowley; Rodrigo Lopez
Journal:  Nucleic Acids Res       Date:  2013-05-13       Impact factor: 16.971

10.  NCBI prokaryotic genome annotation pipeline.

Authors:  Tatiana Tatusova; Michael DiCuccio; Azat Badretdin; Vyacheslav Chetvernin; Eric P Nawrocki; Leonid Zaslavsky; Alexandre Lomsadze; Kim D Pruitt; Mark Borodovsky; James Ostell
Journal:  Nucleic Acids Res       Date:  2016-06-24       Impact factor: 16.971

View more
  7 in total

1.  "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli Cystic Fibrosis Isolates.

Authors:  Elise T Zeiser; Scott A Becka; Brigid M Wilson; Melissa D Barnes; John J LiPuma; Krisztina M Papp-Wallace
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

2.  In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia Species.

Authors:  Krisztina M Papp-Wallace; Adam B Shapiro; Scott A Becka; Elise T Zeiser; John J LiPuma; Douglas J Lane; Rekha G Panchal; John P Mueller; John P O'Donnell; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

3.  Whole Genome Sequence Analysis of Burkholderia contaminans FFH2055 Strain Reveals the Presence of Putative β-Lactamases.

Authors:  José J Degrossi; Cindy Merino; Adela M Isasmendi; Lorena M Ibarra; Chelsea Collins; Nicolás E Bo; Mariana Papalia; Jennifer S Fernandez; Claudia M Hernandez; Krisztina M Papp-Wallace; Robert A Bonomo; Miryam S Vazquez; Pablo Power; María S Ramirez
Journal:  Curr Microbiol       Date:  2019-02-19       Impact factor: 2.188

4.  The Class A β-Lactamase Produced by Burkholderia Species Compromises the Potency of Tebipenem against a Panel of Isolates from the United States.

Authors:  Scott A Becka; Elise T Zeiser; John J LiPuma; Krisztina M Papp-Wallace
Journal:  Antibiotics (Basel)       Date:  2022-05-17

5.  Characterization of the AmpC β-Lactamase from Burkholderia multivorans.

Authors:  Scott A Becka; Elise T Zeiser; Melissa D Barnes; Magdalena A Taracila; Kevin Nguyen; Indresh Singh; Granger G Sutton; John J LiPuma; Derrick E Fouts; Krisztina M Papp-Wallace
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

6.  Assessing the Potency of β-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase from Burkholderia multivorans.

Authors:  Michiyoshi Nukaga; Michael J Yoon; Magdalena A Taracilia; Tyuji Hoshino; Scott A Becka; Elise T Zeiser; Joseph R Johnson; Krisztina M Papp-Wallace
Journal:  ACS Infect Dis       Date:  2021-03-16       Impact factor: 5.084

7.  Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli.

Authors:  Scott A Becka; Elise T Zeiser; John J LiPuma; Krisztina M Papp-Wallace
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.